Regulation of the MIR155 host gene in physiological and pathological processes

Gene

Volumn 532, Issue 1, 2013, Pages 1-12

  Elton, Terry S ^a,b   Selemon, Helina ^a   Elton, Shane M ^c   Parinandi, Narasimham L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Cancer; Cardiovascular disease; Gene regulation; Hematopoiesis; Immunity; MiRNAs

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; MICRORNA 155;

ADIPOGENESIS; B CELL LYMPHOMA; B LYMPHOCYTE; BIOGENESIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION (PARAMETERS); DOWN SYNDROME; GENE CLUSTER; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; HEMATOPOIETIC CELL; HUMAN; IMMUNITY; INFLAMMATION; MACROPHAGE; MOLECULAR MECHANICS; MONOCYTE; MYELOPOIESIS; NEOPLASM; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RNA ANALYSIS; T LYMPHOCYTE; TRISOMY 21; VIRUS INFECTION;

3′-UNTRANSLATED REGION; 3′-UTR; 3T3-L1; A FAMILY OF SMALL NONPROTEIN-CODING RNAS; ACTIVATION-INDUCED CYTIDINE DEAMINASE; ACTIVATOR PROTEIN 1; ACUTE MYELOID LEUKEMIA; AICDA; AML; AN EBV-IMMORTALIZED B-CELL LYMPHOBLASTOID CELL LINE; ANG II; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR; AP-1; ARGININE TO GLUTAMINE AMINO ACID CHANGE AT POSITION 1699 IN THE BRCA1 GENE; AT(1)R; B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B-CELL INTEGRATION CLUSTER; B-CLL; BACH1; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1; BIC; BMDM; BONE MARROW-DERIVED MACROPHAGES; BRCA1; BREAST CANCER 1, EARLY ONSET; BT-549; BURKITT'S LYMPHOMA CELL LINE; C-JUN N-TERMINAL KINASE; C/EBPΒ; CAMP RESPONSE ELEMENT-BINDING; CANCER; CARBON CATABOLITE REPRESSOR PROTEIN 4-GENERAL NEGATIVE REGULATOR OF TRANSCRIPTION; CARDIOVASCULAR DISEASE; CCAAT/ENHANCER-BINDING PROTEIN Β; CCR4-NOT; CELL LINE DERIVED FROM 3T3 CELLS; CERNAS; CFH; CHIP; CHROMATIN IMMUNOPRECIPITATION; COMPETING ENDOGENOUS RNAS; COMPLEMENT FACTOR H; COMPLEMENTARY " STAR FORM" OF MIRNA STRAND; CPG; CREB; CYTOSINE (PHOSPHODIESTER BOND) GUANINE; DCP1/2; DECAPPING ENZYME HOMOLOGS A, B, AND 2; DG75; DGCR8; DIFFUSE LARGE B-CELL LYMPHOMA; DLBCL; DOWN SYNDROME; DROSHA AND THE DIGEORGE CRITICAL REGION 8 PROTEIN; DS; E26 TRANSFORMATION-SPECIFIC; EBNA2; EBV; EBV NUCLEAR ANTIGEN 2; EPSTEIN-BARR VIRUS; ERBB2; ETS; ETS1; FADD; FAS (TNRFSF6)-ASSOCIATED VIA DEATH DOMAIN; FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG B; FORKHEAD BOX P3; FOSB; FOXP3; GENE REGULATION; H2A; H3; H3K4; H3K9; HDACS; HEMATOPOIESIS; HEMATOPOIETIC STEM-PROGENITOR CELLS; HISTONE DEACETYLASE COMPLEXES; HISTONE H2A; HISTONE H3; HL-60; HOMEOBOX PROTEIN; HOXA9; HPBMC; HSA21; HSPCS; HUMAN ACUTE MONOCYTIC LEUKEMIA CELL LINE; HUMAN BREAST CARCINOMA CELL LINE; HUMAN CHROMOSOME 21; HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS; HUMAN PROMYELOCYTIC LEUKEMIA CELL LINE; IΚBΑ; IFN-Β/Γ; IKBKE; IL-10; IL17RB; IMMORTALIZED MYELOGENOUS ERYTHROLEUKEMIA CELL LINE; IMMUNITY; INF-Α/Β; INHIBITOR OF NF-ΚB SUBUNIT EPSILON; INOSITOL POLYPHOSPHATE-5-PHOSPHATASE, 145KDA (A.K.A. SHIP1); INPP5D; INTERFERON BETA/GAMMA; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR ELEMENT; INTERFERON-ALPHA/BETA; INTERFERON-SENSITIVE RESPONSE ELEMENT; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 3; INTERLEUKIN-10; INTERLEUKIN-17 RECEPTOR B; IRAK3; IRF3; IRFE; ISRE; JARID2; JNK; JUMONJI, AT RICH INTERACTIVE DOMAIN 2; JUNB; JY; K562; KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS; KH-TYPE SPLICING REGULATORY PROTEIN; KHSRP; KSHV; LATENT MEMBRANE PROTEIN 1; LIPOPOLYSACCHARIDE; LMP1; LPS; LYSINE 4 OF HISTONE H3; LYSINE 9 OF HISTONE 3; MAREK'S DISEASE VIRUS; MC3; MDV; MECP2; MEIS1; METHYL-CPG-BINDING PROTEIN; MIR-155 HOST GENE; MIR-155*; MIR-155-3P; MIR155HG; MIRISC; MIRNA*; MIRNA-INDUCED SILENCING COMPLEX; MIRNAS; MIRSNP; MOTHERS AGAINST DECAPENTAPLEGIC HOMOLOG; MYB; MYD88; MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE 88; NCRNAS; NF-ΚB; NF-ΚB INHIBITOR, ALPHA; NOD; NON-CODING RNAS; NUCLEAR FACTOR ΚB; NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN-CONTAINING PROTEIN; OPEN READING FRAME; ORF; P53; PBX; PCCD4; PDCS; PEL; PKC; PLASMACYTOID DENDRITIC CELLS; PMBL; POLY(I:C); POLYRIBOINOSINIC: POLYRIBOCYTIDYLIC ACID; PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR; PRE-MIRNAS; PREMATURE MIRNAS; PRI-MIRNAS; PRIMARY EFFUSION LYMPHOMA; PRIMARY MEDIASTINAL B-CELL LYMPHOMA; PRIMARY TRANSCRIPTS OF MIRNAS; PROGRAMMED CELL DEATH PROTEIN 4; PROTEIN KINASE C; R1699Q; RECEPTOR (TNFRSF)-INTERACTING SERINE-THREONINE KINASE 1; REGULATORY T-CELLS; RETINOIC ACID-INDUCIBLE GENE I; RIG-I; RIPK1; S-PHASE KINASE-ASSOCIATED PROTEIN 2; SATB1; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; SINGLE NUCLEOTIDE POLYMORPHISM; SKP2; SMAD; SNP; SNP IN A MIRNA TARGET SITE; SOCS; SOCS1; SPECIAL AT-RICH BINDING PROTEIN-1; SPI1; SPLEEN FOCUS FORMING VIRUS (SFFV) PROVIRAL INTEGRATION ONCOGENE (A.K.A. PU.1); STAT3; SUPPRESSOR OF CYTOKINE SIGNALING 1; TAB2; TCF12; TGF-Β; TGF-Β ACTIVATED KINASE 1/MAP3K7 BINDING PROTEIN 2; THP-1; TLR; TNF-Α; TOLL-LIKE RECEPTOR; TRANSCRIPTION FACTOR 12; TRANSCRIPTION FACTOR JUN-B; TRANSFORMING GROWTH FACTOR BETA; TREGS; TRISOMY 21; TS21; TUMOR NECROSIS FACTOR-ALPHA; TUMOR PROTEIN 53; V-ERB-B2 ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2; V-ETS ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG 1 (AVIAN); V-MYB MYELOBLASTOSIS VIRAL ONCOGENE HOMOLOG; VESICULAR STOMATITIS VIRUS; VIRAL MYOCARDITIS; VM; VSV; ZINC FINGER PROTEIN 652; ZNF652;

ANIMALS; B-LYMPHOCYTES; CARDIOVASCULAR DISEASES; CELL DIFFERENTIATION; DOWN SYNDROME; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MACROPHAGES; MICRORNAS; MULTIGENE FAMILY; NEOPLASMS; NF-KAPPA B; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1;

EID: 84885386910     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.12.009     Document Type: Review

References (167)

1. Adorno M., et al. A mutant-p53/Smad complex opposes p63 to empower TGF2-induced metastasis. Cell 2009, 137:87-98.
2. Akira S., Takeda K. Toll-like receptor signaling. Nat. Rev. Immunol. 2004, 4:499-511.
3. Babar I.A., et al. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1695-E1704.
4. Banerjee A., Schambach F., DeJong C.S., Hammond S.M., Reiner S.L. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur. J. Immunol. 2010, 40:225-231.
5. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
6. Behm-Ansmant I., Rehwinkel J., Doerks T., Stark A., Bork P., Izaurralde E. RNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes Dev. 2006, 20:1885-1898.
7. Boss I.W., et al. A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rγnull mice. J. Virol. 2011, 85:9877-9886.
8. Brennecke J., Stark A., Russell R.B., Cohen S.M. Principles of microRNA-target recognition. PLoS Biol. 2005, 3:e85.
9. Brown B.D., et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 2007, 25:1457-1467.
10. Bushati N., Cohen S.M. microRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23:175-205.
11. Cawthorn W.P., Sethi K. TNF-[alpha] and adipocyte biology. FEBS Lett. 2008, 582:117-131.
12. Ceolotto G., et al. Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. Am. J. Hypertens. 2011, 24:241-246.
13. Ceppi M., et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2735-2740.
14. Chang S., et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat. Med. 2011, 17:1275-1282.
15. Chendrimada T.P., et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005, 436:740-744.
16. Chendrimada T.P., et al. microRNA silencing through RISC recruitment of eIF6. Nature 2007, 447:823-828.
17. Cheng W., et al. microRNA-155 regulates angiotensin II type 1 receptor expression in umbilical vein endothelial cells from severely pre-eclamptic pregnant women. Int. J. Mol. Med. 2011, 27:393-399.
18. Cobb B.S., et al. A role for Dicer in immune regulation. J. Exp. Med. 2006, 203:2519-2527.
19. Corsten M.F., et al. MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis. Circ. Res. 2012, 11:415-425.
20. Costinean S., et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7024-7029.
21. Cremer T.J., et al. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response. PLoS One 2009, 4:e8508.
22. Doench J.G., Sharp P.A. Specificity of microRNA target selection in translational repression. Genes Dev. 2004, 18:504-511.
23. Dombkowski A.A., Sultana Z., Craig D.B., Jamil H. In silico analysis of combinatorial microRNA activity reveals target genes and pathways associated with breast cancer metastasis. Cancer Inform. 2011, 10:13-29.
24. Draheim C.C., McCubbin J.A., Williams D.P. Differences in cardiovascular disease risk between nondiabetic adults with mental retardation with and without Down syndrome. Am. J. Ment. Retard. 2002, 107:201-211.
25. Eis P.S., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3627-3632.
26. Elton T.S., Sansom S.E., Martin M.M. Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins. RNA Biol. 2010, 7:540-547.
27. Elton T.S., Sansom S.E., Martin M.M. Cardiovascular disease, single nucleotide polymorphisms; and the renin angiotensin system: is there a microrna connection?. Int. J. Hypertens 2010, (Article ID 281692, 13 pages). 10.4061/2010/281692.
28. Eulalio A., et al. Target-specific requirements for enhancers of decapping in miRNA-mediated gene silencing. Genes Dev. 2007, 21:2558-2570.
29. Fabani M.M., et al. Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res. 2010, 38:4466-4475.
30. Fabian M.R., Sonenberg N. The mechanics of miRNA mediated gene silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 2012, 19:586-593.
31. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 2:102-114.
32. Forrest A.R., et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010, 24:460-466.
33. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 1:92-105.
34. Fulci V., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109:4944-4951.
35. Gardiner K., Costa A.C. The proteins of human chromosome 21. Am. J. Med. Genet. 2006, 142C:196-205.
36. Gatto G., et al. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res. 2008, 36:6608-6619.
37. Georgantas R.W., et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2750-2755.
38. Giraldez A.J., et al. Zebrafish MiR-430 promotes deadenylation and clearance of maternal mRNAs. Science 2006, 312:75-79.
39. Goi G., Baquero-Herrera C., Licastro F., Dogliotti G., Corsi M.M. Advanced oxidation protein products (AOPP) and high-sensitive C-reactive protein (hs-CRP) in an 'atheroma-free model': Down's syndrome. Int. J. Cardiol. 2006, 113:427-429.
40. Gottwein E., et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007, 450:1096-1099.
41. Gottwein E., et al. Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines. Cell Host Microbe 2011, 10:515-526.
42. Greene A.K., et al. Risk of vascular anomalies with Down syndrome. Pediatrics 2008, 121:135-140.
43. Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123:631-640.
44. Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004, 32:D109-D111.
45. Grimson A., et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
46. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
47. Haasch D., et al. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell. Immunol. 2002, 217:78-86.
48. Hon L.S., Zhang Z. The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression. Genome Biol. 2007, 8:R166.
49. Hu Y.L., Fong S., Largman C., Shen W.F. HOXA9 regulates miR-155 in hematopoietic cells. Nucleic Acids Res. 2010, 38:5472-5478.
50. Hui A.B., et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab. Invest. 2009, 89:597-606.
51. Humphreys D.T., Westman B.J., Martin D.I., Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:16961-16966.
52. Imaizumi T., et al. IFN-γ and TNF-α synergistically induce microRNA-155 which regulates TAB2/IP-10 expression in human mesangial cells. Am. J. Nephrol. 2010, 32:462-468.
53. Iorio M.V., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
54. Izon D.J., et al. Loss of function of the homeobox gene Hoxa-9 perturbs early T-cell development and induces apoptosis in primitive thymocytes. Blood 1998, 92:383-393.
55. Jay C., Nemunaitis J., Chen P., Fulgham P., Tong A.W. MiRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007, 26:293-300.
56. Jiang J., Lee E.J., Schmittgen T.D. Increased expression of microRNA-155 in Epstein-Barr virus transformed lymphoblastoid cell lines. Genes Chromosomes Cancer 2006, 45:103-106.
57. Jiang S., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70:3119-3127.
58. Kasashima K., Nakamura Y., Kozu T. Altered expression profiles of microRNAs during TPA-induced differentiation of HL-60 cells. Biochem. Biophys. Res. Commun. 2004, 322:403-410.
59. Kastner P., Chan S. PU.1: a crucial and versatile player in hematopoiesis and leukemia. Int. J. Biochem. Cell Biol. 2008, 40:22-27.
60. Kaufmann W.E., Johnston M.V., Blue M.E. MeCP2 expression and function during brain development: implications for Rett syndrome's pathogenesis and clinical evolution. Brain Dev. 2005, 27:77-87.
61. Kawagoe H., Humphries R.K., Blair A., Sutherland H.J., Hogge D.E. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 1999, 13:687-698.
62. Keck-Wherley J., et al. Abnormal microRNA expression in Ts65Dn hippocampus and whole blood: contributions to Down syndrome phenotypes. Dev. Neurosci. 2011, 33:451-467.
63. Khvorova A., Reynolds A., Jayasena S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115:209-216.
64. Kim V.N., Han J., Siomi M.C. Biogenesis of small RNAs in animals. Nat. Rev. Mol. Cell Biol. 2009, 10:126-139.
65. Kluiver J., et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 2005, 207:243-249.
66. Kluiver J., et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 2006, 45:147-153.
67. Kluiver J., et al. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene 2007, 26:3769-3776.
68. Koch M., Mollenkopf H.J., Klemm U., Meyer T.F. Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-damage induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:1153-1162.
69. Kohlhaas S., et al. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J. Immunol. 2009, 182:2578-2582.
70. Kong W., et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28:6773-6784.
71. Kong W., et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 2010, 285:17869-17879.
72. Krek A., et al. Combinatorial microRNA target predictions. Nat. Genet. 2005, 7:495-500.
73. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11:597-610.
74. Kuhn D.E., et al. Experimental validation of miRNA targets. Methods 2008, 44:47-54.
75. Ladoire S., et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2011, 125:65-72.
76. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002, 12:735-739.
77. Lam L.T., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin. Cancer Res. 2005, 11:28-40.
78. Landgraf P., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401-1414.
79. Lau N.C., Lim L.P., Weinstein E.G., Bartel D.P. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001, 294:858-862.
80. Lawrence H.J., et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 2005, 106:3988-3994.
81. Lee E.J., et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120:1046-1054.
82. Leung A.K., Sharp P.A. MicroRNA functions in stress responses. Mol. Cell 2010, 40:205-215.
83. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
84. Li Y.Y., et al. miRNA-155 upregulation and complement factor H deficits in Down's syndrome. NeuroReport 2012, 23:168-173.
85. Linnstaedt S.D., Gottwein E., Skalsky R.L., Luftig M.A., Cullen B.R. Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J. Virol. 2010, 84:11670-11678.
86. Liu N., Olson E.N. MicroRNA regulatory networks in cardiovascular development. Dev. Cell 2010, 18:510-525.
87. Liu S., Yang Y., Wu J. TNFa-induced up-regulation of miR-155 inhibits adipogenesis by down-regulating early adipogenic transcription factors. Biochem. Biophys. Res. Commun. 2011, 414:618-624.
88. Lu F., et al. Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. J. Virol. 2008, 82:10436-10443.
89. Lu L.F., et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009, 30:80-91.
90. Mao C.P., et al. In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell Biosci. 2011, 1:3.
91. Marson A., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445:931-935.
92. Masaki S., Ohtsuka R., Abe Y., Muta K., Umemura T. Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem. Biophys. Res. Commun. 2007, 364:509-514.
93. Mathonnet G., et al. microRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 2007, 317:1764-1767.
94. Mattiske S., Suetani R.J., Neilsen P.M., Callen D.F. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Biomarkers Prev. 2012, 21:1236-1243.
95. McCoy C.E., et al. IL-10 inhibits miR-155 induction by toll-like receptors. J. Biol. Chem. 2010, 285:20492-20498.
96. McInnes N., et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012, 31:1045-1054.
97. Mehta P.K., Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 2007, 292:C82-C97.
98. Mendell J.T., Olson E.N. MicroRNAs in stress signaling and human disease. Cell 2012, 148:1172-1187.
99. Miyoshi K., Miyoshi T., Siomi H. Many ways to generate microRNA-like small RNAs: non-canonical pathways for microRNA production. Mol. Genet. Genomics 2010, 284:95-103.
100. Morgan R., et al. Sequence conservation and differential expression of Marek's disease virus microRNAs. J. Virol. 2008, 82:12213-12220.
101. Morrison R.A., et al. Low blood pressure in Down's syndrome: a link with Alzheimer's disease?. Hypertension 1996, 28:569-575.
102. Muljo S.A., et al. Aberrant T cell differentiation in the absence of Dicer. J. Exp. Med. 2005, 202:261-269.
103. Muller P.A., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
104. Mullokandov G., et al. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat. Methods 2012, 9:840-846.
105. Murugaiyan G., Beynon V., Mittal A., Joller N., Weiner H.L. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 2011, 187:2213-2221.
106. Neilsen P.M., et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene J. 2013, 32:2992-3000.
107. Nielsen C.B., et al. Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA 2007, 13:1894-1910.
108. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 2008, 93:1600-1608.
109. O'Connell R.M., Taganov K.D., Boldin M.P., Cheng G., Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1604-1609.
110. O'Connell R.M., et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 2008, 205:585-594.
111. O'Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:7113-7118.
112. Okamura K., et al. The regulatory activity of microRNA* species has substantial influence on microRNA and 3' UTR evolution. Nat. Struct. Mol. Biol. 2008, 15:354-363.
113. Packer A.N., Xing Y., Harper S.Q., Jones L., Davidson B.L. The bifunctional microRNA, miR-9/miR-9*, regulates REST and CoREST and is downregulated in Huntington's disease. J. Neurosci. 2008, 28:14341-14346.
114. Pillai R.S., et al. Inhibition of translational initiation by let-7 microRNA in human cells. Science 2005, 309:1573-1576.
115. Ramkissoon S.H., et al. Hematopoieticspecific microRNA expression in human cells. Leuk. Res. 2006, 30:643-647.
116. Ranganathan P., et al. Regulation of acute graft-versus-host disease by microRNA-155. Blood 2012, 119:4786-4797.
117. Reeves R.H., et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 1995, 11:177-184.
118. Rodriguez A., et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316:608-611.
119. Roizen N.J., Patterson D. Down's syndrome. Lancet 2003, 361:1281-1289.
120. Rüegger S., Großhans H. MicroRNA turnover: when, how, and why. Trends Biochem. Sci. 2012, 37:436-446.
121. Ruggiero T., et al. LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J. 2009, 23:2898-2908.
122. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
123. Satge D., Sasco A.J., Azema B., Culine S. Cancers in persons with intellectual deficiency: current data. Mental retardation research focus 2007, 47-84. Nova Sciences Publisher, New York NY.
124. Schwarz D.S., et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115:199-208.
125. Scott M.S., Ono M. From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie 2011, 93:1987-1992.
126. Sethupathy P., et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am. J. Hum. Genet. 2007, 81:405-413.
127. Shanmugam K., Green N.C., Rambaldi I., Saragovi H.U., Featherstone M.S. PBX and MEIS as non-DNA-binding partners in trimeric complexes with HOX proteins. Mol. Cell. Biol. 1999, 19:7577-7588.
128. Shen W.F., et al. The Abd-B-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins. Mol. Cell. Biol. 1997, 17:6448-6458.
129. Shen W.F., et al. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol. Cell. Biol. 1999, 19:3051-3061.
130. Shin C. Cleavage of the star strand facilitates assembly of some microRNAs into Ago2-containing silencing complexes in mammals. Mol. Cell 2008, 26:308-313.
131. Skalsky R.L., et al. Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155. J. Virol. 2007, 81:12836-12845.
132. Stanczyk J., et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008, 58:1001-1009.
133. Szafranska A.E., et al. MicroRNA expression alterations are linked to tumorigenesis and nonneoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
134. Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12481-12486.
135. Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 2001, 274:157-167.
136. Tam W., Ben-Yehuda D., Hayward W.S. bic, a novel gene activated by proviral insertions in avian leukosis virus-induced lymphomas, is likely to function through its noncoding. RNA. Mol. Cell. Biol. 1997, 17:1490-1502.
137. Tarassishin L., et al. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia 2011, 59:1911-1922.
138. Thai T.H., et al. Regulation of the germinal center response by microRNA-155. Science 2007, 316:604-608.
139. Thermann R., Hentze M.W. Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature 2007, 447:875-878.
140. Thompson R.C., Herscovitch M., Zhao I., Ford T.J., Gilmore T.D. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J. Biol. Chem. 2011, 286:1675-1682.
141. Tili E., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5982-5989.
142. Tili E., et al. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis 2010, 31:1561-1566.
143. van den Berg A., et al. High expression of B-cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma. Genes Chromosomes Cancer 2003, 37:20-28.
144. van Rooij E., Purcell A.L., Levin A.A. Developing microRNA therapeutics. Circ. Res. 2012, 110:496-507.
145. Vargova K., et al. MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood 2011, 117:3816-3825.
146. Vigorito E., et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007, 27:847-859.
147. Volinia S., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2257-2261.
148. Wakiyama M., Takimoto K., Ohara O., Yokoyama S. Let-7 microRNA-mediated mRNA deadenylation and translational repression in a mammalian cell-free system. Genes Dev. 2007, 21:1857-1862.
149. Wang X., et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3:e2557.
150. Wang P., et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J. Immunol. 2010, 185:6226-6233.
151. Wang L., et al. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression. J. Virol. 2011, 85:8328-8337.
152. Westholm J.O., Lai E.C. Mirtrons: microRNA biogenesis via splicing. Biochimie 2011, 93:1897-1904.
153. Worm J., et al. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp beta and down-regulation of g-CSF. Nucleic Acids Res. 2009, 37:5784-5792.
154. Wu L., Fan J., Belasco J.G. microRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4034-4039.
155. Xiao B., et al. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J. Infect. Dis. 2009, 200:916-925.
156. Yanaihara N., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
157. Yang J.S., et al. Widespread regulatory activity of vertebrate microRNA* species. RNA 2011, 17:312-326.
158. Yarden R.I., Brody L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:4983-4988.
159. Yin Q., Wang X., McBride J., Fewell C., Flemington E. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J. Biol. Chem. 2008, 283:2654-2662.
160. Yin Q., et al. MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates Epstein-Barr virus-regulated gene expression pathways. J. Virol. 2008, 82:5295-5306.
161. Zhang Y., et al. LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood 2012, 120:1678-1686.
162. Zhao Y., et al. A functional MicroRNA-155 ortholog encoded by the oncogenic Marek's disease virus. J. Virol. 2009, 83:489-492.
163. Zhao Y., et al. Critical role of the virus-encoded microRNA-155 ortholog in the induction of Marek's disease lymphomas. PLoS Pathog. 2011, 7:e1001305.
164. Zheng Y., et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
165. Zheng L., et al. MicroRNA-155 regulates angiotensin II type 1 receptor expression and phenotypic differentiation in vascular adventitial fibroblasts. Biochem. Biophys. Res. Commun. 2010, 400:483-488.
166. Zhou H., et al. miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 2010, 116:5885-5894.
167. Zuo T., et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J. Clin. Invest. 2007, 117:3765-3773.